The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional marketing authorization for treatment of two different diseases: the rare ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease. Sean Korbitz had his first bout with cancer — a brain tumor discovered after six ...

When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like ...

The familial cancer syndrome, von Hippel–Lindau (VHL) disease, characterized by a predisposition to renal cell carcinoma and certain other tumor types, is caused by mutational inactivation of the VHL ...

Decision marks first approval for WELIREG in China and 17th approval of WELIREG for these patients globally In August 2021, WELIREG was approved in the U.S. for the treatment of adult patients with ...

uring the 1990s, several labs in the United States and United Kingdom investigated the von Hippel-Lindau tumor suppressor (pVHL). Many important findings developed, including the belief that HIF ...

Tumour suppressor genes and oncogenes are often involved, directly or indirectly, in the regulation of transcription. New opportunities for large-scale analysis of the downstream patterns of abnormal ...

At age 16, Julia Máté noticed something wrong with her vision. But she could never have predicted the diagnosis, and huge decision, that would come decades later. "I noticed that I had a black curtain ...

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results Patients diagnosed with hereditary RC are more prone to ...

WELIREG is the first and only systemic therapy approved in China for adult patients with certain VHL disease-associated tumors Decision marks first approval for WELIREG in China and 17th approval of ...